Corona vaccination is the key
Regarding results in Chili and Israel, after high speed vaccination, 60+ population are no longer admitted to hospitals. Israel is slowly returning to 'normal life' after vaccinating half of its population. That would mainly have happened through the Pfizer vaccine. 45 percent of the 9 million inhabitants would already have had one shot with the drug. Administering two doses of vaccine has reduced the amount of COVID-19 infections expected by 95.8 percent, Reuters writes, based on government data.
The director of American pharmaceutical company Johnson & Johnson, Alex Gorsky told that people may need to get a new corona vaccination every year for the next few years, just like with the annual flu shot. (14-02-2021)
About the effect of vaccinations, the vaccination program in Scotland is leading to a significant decrease in the number of hospital admissions. Researchers from the Universities of Edinburgh, Strathclyde and the Scottish Health Service report that the Pfizer / BioNTech vaccine reduces the risk of hospitalization by 85 percent. With the AstraZeneca vaccine this is even 94 percent. (22-02-2021)
Brussels has now ordered at least 1.4 billion doses of the vaccines already authorized in the EU. That should be more than enough for the approximately 450 million Europeans. (14-03-2021)
You are not slowing down the epidemic
Mortality rate will drop sharply after first vaccinations, but the spread of the virus will not. "It is mainly young people and middle-aged people who transmit the virus to others." Alma Tostmann of the Radboudumc also warns against too high expectations. "I want to prevent people from thinking that the danger has passed. Because if we do everything we want again, the virus could move to another part of society that is at risk of illness or death," says the epidemiologist." Even in the slightly younger layer of the population, people have underlying diseases, there are long-term corona patients and people end up in IC. "RIVM data shows that 90 percent of all registered corona deaths occur attribute to the age group 70+ (04-01-2021)
Worldwide, researchers are working on 200+ vaccines
"We know that the vaccines prevent mild cases of COVID-19. This means that if vaccinated people already develop a coronavirus infection, they are more likely to be sick for a shorter period of time and cough and cough less. This makes them less likely to pass on the coronavirus." Akiko Iwasaki, an immunologist at Yale University, told The New York Times that vaccinated people would be less contagious than unvaccinated people after an unexpected coronavirus infection. (18-02-2021)
Corona vaccination | The Netherlands
- 6 million injections in May,
- 11 million injections at the beginning of June,
- 18 million injections at the beginning of July.
- Two thirds of the people are then fully vaccinated and one third only will have 1 shot.
- The current population of the Netherlands is 17,159,103. (23-03-2021)
- Pfizer - vaccine (95 percent effective)
- Moderna - vaccine (94 percent effective)
- Janssen - vaccine (66 percent effective)
- AstraZeneca - vaccine (60 percent effective)
- CureVac - vaccine (study ongoing).
Pfizer director Marc Kaptein: re-vaccination against Covid-19 is "inescapable"
Marc Kaptein, the director at Pfizer Netherlands, does not think that when all Dutch people willing to vaccinate have gotten one or two injections this summer, there will never be a need for corona vaccination campaigns in our country again. On the contrary, a new vaccination campaign to give Dutch people so-called "booster shots" is even inevitable: "We cannot avoid revaccination," he says presenter Wilson Boldewijn.
The European Union clearly agrees with the top boss of the Dutch branch of the pharmaceutical company that develops and manufactures the acclaimed Pfizer / BioNTech vaccine. In the coming years, Brussels will buy another 1.8 billion vaccines - enough to vaccinate every European citizen several times against potentially emerging corona variants that escape the effects of vaccines such as those from Pfizer. (26-04-2021)
Syria receives first corona vaccines
Syria has received its first shipment of corona vaccines through COVAX, an initiative by UNICEF and WHO to help poorer countries get vaccines. A total of 256,800 doses were brought into the country, of which 203,000 in the capital Damascus and 53,800 in the northwest of the country, where heavy fighting often takes place. In Syria, health workers are the first to be vaccinated. (23-04-2021)
AstraZeneca updates package insert due to rare side effect of vaccine
The British-Swedish pharmaceutical company AstraZeneca is updating the package insert for the vaccine against COVID-19 because of the very rare side effect of thrombosis and a lack of platelets that can occur after a shot.
The company is also investigating the side effects. AstraZeneca reports in a statement tonight that the vaccine maker is trying to find out what happened in all cases of serious side effects.
The European Medicines Agency (EMA) officially designated the rare form of thrombosis and platelet deficiency today as a very rare side effect of the AstraZeneca vaccine. Despite this, the benefit the vaccine provides is still greater than the risks it poses, the authority said.
According to the EMA, an exact risk of the side effect cannot yet be given, but based on reports, the medicines authority expects this to be 1 in 100,000. (07-04-2021)
More than 100 million US residents have received at least one injection
The United States reached a new milestone in the vaccination campaign on Friday: the number of people who received at least one shot has risen to over 100 million.
According to the latest figures, 101.8 million people have been vaccinated, almost a third of the US population of 330 million people. About 58 million people are considered fully vaccinated. In the particularly vulnerable age group of over-65s, three quarters have already received a vaccination and more than half have now received maximum protection. (03-04-2021)
EU Countries that have suspended the use of AstraZeneca for a short time
The Netherlands, Germany, Spain, France, Italy, Denmark, Iceland, Bulgaria, Latvia and Norway. Millions of people in the UK have already been vaccinated with the AstraZeneca vaccine. "Yes, I can," Johnson replied when asked if he could reassure people. Johnson says the British medicine watchdog sees "no reason" to change the vaccination program in his country. The Netherlands decided to temporarily stop the injection process with the AstraZeneca (16-03-2021)
Update: People who have canceled their appointment for a vaccination with the AstraZeneca vaccine can reschedule if they wish. Only people who prefer a different vaccine will be "at the back of the queue" and will therefore have to wait longer for an injection against COVID-19, says a spokesman for outgoing minister Hugo de Jonge. (18-03-2021)
Pfizer doubles the deliveries to the Netherlands: 500.000 doses p. week
Pharmaceuticals BioNTech and Pfizer are delivering considerably more vaccines than expected in a short time, writes outgoing Health Minister Hugo de Jonge on Twitter on Tuesday. From April onwards, the Netherlands will receive half a million vaccine doses from pharmaceuticals every week, while more than 200,000 doses a week were initially expected. (02-03-2021)
BioNTech / Pfizer
One of the most advanced vaccines comes from pharmaceutical company Pfizer, which collaborates with BioNTech. Pfizer's shot is a so-called mRNA vaccine. This contains genetic information with which, once guy in the body, pieces of the corona virus can be made. These pieces cannot cause you to get COVID-19, but they do cause the immune system to produce antibodies against the coronavirus. These antibodies protect you - if it works properly - if you really encounter the corona virus later on. 2nd edition of this vaccine is available by end summer 2021.
Janssen & Janssen
Developer Janssen's injection contains a cold virus. This virus has been modified so that you cannot become ill and, once injected, ensures that pieces of the corona virus are made in the body. With this vaccine, too, you cannot get COVID-19 from these coronavirus pieces. The pieces do ensure that you build up resistance.
AstraZeneca's vaccine is very similar to Janssen's shot. However, a cold virus that occurs in humans has not been used, but in chimpanzees. What is striking about the study results is that the effectiveness of the vaccine increased when test subjects first received half a dose and then a full dose. The vaccine appeared to be no less than 90 percent effective in this group. It is still unclear why this method of vaccination appears to be more effective. This is being investigated further.
Update: After one shot with the AstraZeneca vaccine, a person is 76 percent protected against the corona virus for up to three months. The chance of infecting someone else is 67 percent less than someone who has not been vaccinated. This is evident from an as yet unpublished study in the renowned British medical journal The Lancet. After the second dose, the vaccine's efficacy is 82.4 percent, the University of Oxford researchers write. In people who received the second shot after six weeks, that protection was 54.9 percent.
Vaccine maker AstraZeneca is providing another 9 million doses of the corona vaccine for the European Union. The pharmaceutical company now promises to deliver a total of 40 million doses to the EU in the first quarter. The company will also increase production capacity in Europe. (02-02-2021)
South Africa has suspended the administration of the AstraZeneca vaccine, Health Minister Zweli Mkhize said during an online news conference. A study of the first test results of the vaccine showed that it offers less protection against mild and moderate symptoms of the South African virus variant. (08-02-2021)
Update: Health organization WHO wants more data on AstraZeneca's corona vaccine, now that it appears that the vaccine offers less protection against mild and moderate symptoms after infection with the South African variant of the virus. (10-02-2021)
Trrombosis or embolism after vaccination. EU Countries that have suspended the use of AstraZeneca: The Netherlands, Germany, Spain, France, Italy, Denmark, Iceland, Bulgaria, Latvia and Norway. Millions of people in the UK have already been vaccinated with the AstraZeneca vaccine. (16-03-2021)
Sanofi / GSK
With the injection of the pharmaceutical company Sanofi / GSK, a piece of the corona virus is directly injected, which should lead to the production of antibodies. The final part of the study is expected to start at the end of 2020 and the pharmaceutical company hopes to deliver the first doses in the third quarter of 2021.
Pharmaceuticals are working on vaccines against more variants
Pharmaceuticals GlaxoSmithKline (GSK) and CureVac are going to collaborate on a new vaccine against the corona virus. They are aiming for a single vaccine that protects against several emerging variants of the virus. The two companies are investing around 150 million euros in the project. New variants of the coronavirus, such as the British and South African mutations, are at risk of spreading much faster. According to GSK and CureVac, rapid steps are needed to "stay one step ahead" of the pandemic.
Their collaborative project builds on the candidate vaccine from the German CureVac, which is still under investigation. This vaccine uses the same new technology as the Pfizer / BioNTech and Moderna vaccines approved in the European Union: mRNA. Through these vaccines, synthetic material with the same genetic code as the proteins of the characteristic protuberances of the corona vaccine is injected. Certain cells in the body therefore make the same proteins. In response, people who are vaccinated also make antibodies to the coronavirus.
CureVac, like Pfizer, is working on the development of an mRNA vaccine. With this vaccine, the body is instructed to produce pieces of coronavirus, which ensure that the immune system produces antibodies. The pharmaceutical company wants to deliver the vaccinations in the second or third quarter of 2021.
Moderna vaccine should be stored at a temperature of -20. However, it can be stored at refrigerator temperature for thirty days. The pharmaceutical company expects to be able to deliver vaccines in the EU in the first or second quarter of 2021. The vaccine, like Pfizer's, is very promising. The Moderna vaccine appears to be 94.5 percent effective, the pharmaceutical company reported on November 16. Moderna, like Pfizer and CureVac, makes an mRNA inoculation. Moderna's research is in its final phase. (24-11-2020)
Back to top
EMA will accelerate assessment of Russian Sputnik vaccine
The EU drug agency EMA has begun the evaluation of the Russian corona vaccine Sputnik. Last month, the manufacturer reported an effectiveness of nearly 92 percent.Preliminary results from the vaccine development study show that it stimulates the production of antibodies and T cells of the immune system against the virus. Proven type of vaccine: The Sputnik vaccine is a so-called vector vaccine, just like the AstraZeneca injection. In general, this is a tried and tested vaccine type, the efficacy of which has been proven. (04-03-2021)
Russian Sputnik V
Available for everyone in Russia. At home, Russia is halving the price of two doses of the Sputnik V vaccine to 866 rubles (9.50 euros). The discount is possible due to the optimization of the production process, said trade minister Denis Manturov. Production has increased significantly since Russia started its vaccination campaign, another reason for a price drop.
The Russian vaccine Sputnik-V is 91.6 percent effective against COVID-19, researchers confirm Tuesday in an article in the British renowned medical journal The Lancet. They based themselves on interim research results. The authors of the paper write that little can be said about its effectiveness in the long term. The effect on asymptomatic infections has also not yet been sufficiently proven, because the effectiveness has only been measured with symptomatic infections. (02-02-2021)
It is a so-called vector vaccine, just like the AstraZeneca injection. In general, this is a proven vaccine type, the efficacy of which has been proven.
The manufacturer of Sputnik V submitted a request for approval to the European Medicines Agency (EMA) on January 20, 2021, the EMA will only assess and possibly approve the drug after the phase-3 studies have been completed and published.
is the first EU member state to purchase the Russian corona vaccine Sputnik V
Rejecting: Lawmakers in Ukraine's parliament have overwhelmingly voted to ban the approval of vaccines made in Russia. (1-2-2021)
The British will accelerate the approval of modified corona vaccines
The British medical regulator will accelerate the approval of vaccines against new variants of the corona virus. Pharmacists who modify a corona vaccine that has already been approved, do not have to do long-term research afterwards to prove that the drug works. Some existing vaccines are feared to be less effective against new variants, including those found in Brazil and South Africa. "It is a priority for us to make effective vaccines available to the public as soon as possible, without compromising on safety," said a top associate of regulator MHRA. (04-03-2021)
The European Commission (EC) has signed a deal with pharmacists Pfizer and BioNTech to supply an additional 200 million doses of the corona vaccine.
The vaccines will probably be delivered before the end of the year 2021 to the 27 EU countries, including the Netherlands. The Netherlands will receive nearly twenty million doses before the end of the year. The Netherlands would already receive 19.5 million doses of the vaccine before the end of the year, enough to vaccinate almost ten million people. For the time being, only people who work in long-term care (such as nursing homes) or in the acute care of hospitals, residents of nursing homes, people with intellectual disabilities and people over 80 living at home will receive the vaccine from Pfizer and BioNTech. (18-02-2021)
Pharmaceutical Johnson & Johnson: May require annual corona vaccination
The director of American pharmaceutical company Johnson & Johnson Alex Gorsky told CNBC on Tuesday that people may need to get a new corona vaccination every year for the next few years, just like with the annual flu shot. According to Gorsky, this has to do with mutation of the virus. In his view, this could affect the effectiveness of the vaccine.
Johnson & Johnson is the parent company of the Leiden pharmaceutical company Janssen. Last week, the company applied to the United States Food and Drug Administration (FDA) for accelerated approval to market its corona vaccine. The pharmaceutical company says it has an efficacy of 66 percent. That's lower than competitors Moderna, Pfizer / BioNTech and AstraZeneca, but the J&J vaccine only requires one shot. Gorsky said in the CNBC interview that it is still on track to deliver 100 million doses to the United States by the end of June. (10-02-2021)
German vaccine factory for Pfizer put into operation
The American pharmaceutical company Pfizer and the German collaboration partner BioNTech have started producing corona vaccines in Germany, Bild reports. The production facility in the German city of Marburg is to produce 750 million doses per year. Pharmacists want to make a total of two billion vaccines for the whole world.
The factory in Marburg opens earlier than expected. Originally, the first doses would roll off the line at the end of February. The European Union announced last month that it plans to purchase an additional 600 million doses from Pfizer and BioNTech. (10-02-2021)
South Africa stops vaccination with AstraZeneca vaccine after disappointing study
South Africa has suspended the administration of the AstraZeneca vaccine, Health Minister Zweli Mkhize said during an online news conference. A study of the first test results of the vaccine showed that it offers less protection against mild and moderate symptoms of the South African virus variant.
South Africa has received 1 million doses of the AstraZeneca vaccine and is expected to start vaccinating people next week. The study has not yet received a peer review, but in light of the results, the government will wait to vaccinate until more advice is available. (08-02-2021)
AstraZeneca vaccine less effective against South African virus
The corona vaccine developed by AstraZeneca and the University of Oxford appears to offer less protection against mild and moderate symptoms caused by the South African virus variant. That writes The Financial Times. (07-02-2021)
Chinese health authorities have approved a second COVID-19 vaccine
The Sinovac Biotech drug is a variant of a Sinopharm vaccine approved in December 2020.
EMA is investigating antibody therapy (which mr. Trump also received)
The European Medicines Agency EMA is investigating the medicines of the American manufacturers Eli Lilly and Regeneron. These are therapies with antibodies. The supervisor will examine whether corona patients who do not need extra oxygen, but who are at high risk of deterioration, benefit from the treatment.
Former US President Donald Trump was experimentally treated with Regeneron's antibody therapy during his October 2020 contamination. The drug had not yet received regulatory approval at that time. Trump later said the drug had "done a fantastic job." Eli Lilly developed a similar therapy.
Germany is the first country in the European Union to start using experimental antibody treatment. The government in Berlin bought 200,000 doses for 400 million euros. (05-02-2021)
The Health Council advises people over 65 not to administer the corona vaccine from pharmaceutical company AstraZeneca and the University of Oxford
The Health Council advises people over 65 not to administer the corona vaccine from pharmaceutical company AstraZeneca and the University of Oxford. The drug is suitable for older people aged 60 to 65, the advisory body wrote to outgoing Hugo de Jonge (Public Health) on Thursday. It is striking that there is still little data available for the age group of 60 to 65 years with which the effectiveness can be determined. Research by the RIVM does show that vaccination of this group can prevent hospital admissions and death in the short term. The Health Council agrees with this.
In addition, too little data is available in people aged 56 and over to calculate the efficacy of the AstraZeneca vaccine. According to the Health Council, the vaccine does induce an immune response in this group that is comparable to that of 18 to 55-year-olds. Too little is known about the efficacy and effectiveness of the AstraZeneca vaccine in people over 65, because they only participated in studies to a limited extent. That was also the reason for countries around us, such as Germany and Belgium, not to administer the vaccine to this target group. (04-03-2021)
Germany has already ordered corona vaccines for 2022
Should these prove necessary later to keep the German population immune or to expand the immunity. German Health Minister Jens Spahn said this Saturday in an online meeting with people from the medical care system. (1-2-2021)
Vaccine maker AstraZeneca is providing another 9 million doses of the corona vaccine
The pharmaceutical company now promises to deliver a total of 40 million doses to the EU in the first quarter. The company will also increase production capacity in Europe. (1-2-2021)
Janssen's Leiden corona vaccine provides 66 percent protection against COVID-19
The corona vaccine developed by pharmaceutical company Janssen from Leiden offers 66 percent protection against COVID-19, parent company Johnson & Johnson reports based on trials. The percentage is considerably lower than with the already approved vaccines from Pfizer / BioNTech and Moderna. According to research, these offer about 90 percent protection. Trials in the United States showed that the vaccine was on average 72 percent effective. Worldwide tests, in which the vaccine was also tested for several variants, showed that the vaccine offers 66 percent protection. In South Africa, where a worrisome variant of the virus (also called the South African variant or mutation) is circulating, the Janssen vaccine protection level was 57 percent. (29-1-2021)
Oxford is working on converting a vaccine against new variants
Scientists at Oxford University are hard at work developing new versions of the AstraZeneca vaccine that are effective against the corona variants from South Africa, Brazil and the United Kingdom, the British newspaper Daily Telegraph reports.
According to the paper, this is happening because the current generation of covid-19 vaccines may not work against the new South African variant. The vaccine scientists are investigating how quickly they can convert their vaccine to be effective against a new variant. That could probably be done in a day or two, a source in Oxford told the newspaper.
According to a university spokesperson, it is "known that viruses are constantly changing through mutation" and we can expect many new variants to be identified by 2021. "These changes are being closely monitored by scientists, and it is important that we remain alert to changes in the future." (21-1-2021)
The AstraZeneca vaccine, the third COVID-19 vaccine
The vaccines from Pfizer-BioNTech and Moderna have already been put into use. The AstraZeneca vaccine is already in use in the United Kingdom. The European Member States have jointly ordered some 400 million vaccine doses from AstraZeneca, of which the Netherlands receives nearly 12 million. Nearly ten million doses should be delivered in the first half year. The cabinet wants to use the vaccine from AstraZeneca and Oxford University for 18 to 60-year-olds, both with and without medical problems. Some of the healthcare workers can also be vaccinated with the drug, although other vaccines are also expected for that target group. As with the Pfizer vaccine, two vaccinations are required for the injection to provide enough protection against the corona virus. The EMA hopes to reach a decision on January 29, the drug agency said in a statement. (12-01-2021)
It started in the Lab, with the L variant in China. The first major mutation, the S variant, appeared in Asia in January 2020. The V and G variant were added in mid-January. The G variant was found in North America and Europe. This species has since mutated into variants we call GR, GH and GV. The other small species are mentioned under O variant. These variants are kept in a database by scientists so that they can continue to track mutations worldwide. (26-12-2020)
The corona virus has been transformed into 7 head variants (270+ transformation exist). Ireland announced on Friday 25-12-2020 that the mutated UK variant has also surfaced there. Currently there are confirmations from: Belgium, Denmark, Finland, France, Germany, Iceland, Italy, the Netherlands, Norway, Portugal, Spain and Sweden) and globally (Australia, Canada, Hong Kong SAR, India, Israel, Japan, Jordan, Lebanon, South Korea, Switzerland, Singapore, Iran, Brazil (09-01-2021).
a) Global vaccination won't begin until the second (Q2) or third quarter (Q3) of 2021. Problems getting enough raw materials for Pfizer / biotechnologist BioNTech. Update: Work is currently being done on a way of making the doses easier to store. Now the vaccine has to be stored at a temperature of -70 degrees. CEO Sahin expects that the next version of the vaccine can also be stored at higher temperatures. That version should be ready by the end of the summer 2021. (01-01-2021)
b) People with a history of severe allergic reactions to medicines, food or vaccinations should not receive a Pfizer / BioNTech vaccination for the time being.
The Dutch population is divided into groups
Change of plan: First, it is the turn of the acute care workers: personnel in ambulances, the emergency department and the IC and Covid wards. So that's part of the original group 4 and 5.
The GPs (doctors) are also given priority, it was decided recently. They will not be added to the first group, which is vaccinated with the Pfizer vaccine, but are the first to be vaccinated with the Moderna vaccine. This is expected to be available at the end of February 2020 after approval by the EMA. (04-01-2020)
Group 1: A. Nursing home residents and people with an intellectual disability in institutions.
B. Care employees of nursing homes, care for the disabled, community nursing and WMO support.
Group 2: People over sixty with and without a medical indication, the oldest age group being the first.
Group 3: People under sixty with a medical indication.
Group 4: The care workers of the people in groups 2 and 3.
Group 5: Healthcare workers who are in direct contact with covid patients.
Group 6: Other healthcare workers.
Group 7: People aged 18-60.
Pfizer vaccine appears to be effective against mutation
British and South African variants Pfizer / BioNTech vaccine also appears to be effective against mutation in the highly contagious variants of the coronavirus found in the UK and Touring South Africa. The company says this based on a laboratory study it carried out together with scientists from the University of Texas. (07-01-2021)
Back to top
Approval for Moderna
The European Medicines Agency (EMA) has approved a vaccine against COVID-19 for the second time, it was announced on Wednesday. The vaccine was developed by the American Moderna and can soon be used in the European Union, just like the vaccine from Pfizer. The corona vaccine is expected to protect 94 percent of vaccinees against COVID-19. The Netherlands has signed a contract with Moderna through the European Commission for 6.2 million doses. Because everyone needs two doses, it can vaccinate 3.1 million people against COVID-19. Moderna is expected to deliver 390,000 doses in the first quarter of this year. (06-01-2021)
Three quarters of the Dutch are willing to be vaccinated
More Dutch people are willing to get vaccinated against the corona virus. Research agency Ipsos questioned Dutch people last week on behalf of the NOS and came to the conclusion that the willingness to vaccinate has increased to 75 percent. (05-01-2021)
Israel also approves Moderna vaccine
The corona vaccine of the American pharmaceutical company Moderna can be used in Israel. It is the third country to officially approve the vaccine after the United States and Canada. The European Medicines Agency (EMA) may approve the vaccine on Wednesday. Moderna plans to produce at least 600 million vaccines this year. Israel has ordered six million doses. The vaccination campaign in the country of nine million inhabitants is proceeding extremely well. In just over two weeks, 1.37 million people have been vaccinated with the first dose of the US-German vaccine from Pfizer / BioNTech. (05-01-2021).
Indonesia begins on January 13, 2021 with Chinese vaccine on a large scale
On January 13, Indonesia starts a major vaccination campaign with the Chinese vaccine from Sinovac Biotech. The first to be vaccinated is President Joko Widodo. The country wants to start vaccinating 1.3 million people who are active in healthcare. (Previously, a test with the Chinese vaccine achieved only 50% result in Brazil). In Indonesia, 772,000 people have been tested positive for the corona virus. Nearly 23,000 COVID-19 patients died from the effects of the virus. (05-01-2021)
Pharmacists and regulator: vaccine efficacy in case of postponement of second injection not proven
Vaccine developers Pfizer and BioNTech warn that there is no evidence that their corona vaccine offers sufficient protection if the second injection is delayed. Several countries choose or are considering giving the second injection not within three weeks, but only later. Pfizer and BioNTech's corona vaccine should be administered twice for maximum protection. The manufacturers use an interval of three weeks. That is also the period that was adhered to when testing the vaccine. "There is no data showing that protection will last beyond the 21-day period," say the manufacturers. (05-01-2021)
Back to top
First vaccination with Oxford / AstrazZeneca vaccine In UK
Vaccination has started with the vaccine from Oxford University and pharmaceutical company AstraZeneca. The first Briton to be injected with the drug outside the test period was 82-year-old kidney patient Brian Pinker. He received it in his hometown of Oxford, several hundred yards from where it was developed. (04-01-2021)
New Pfizer in 2021
Work is currently being done on a way of making the doses easier to store. Now the vaccine has to be stored at a temperature of -70 degrees. CEO Sahin expects that the next version of the vaccine can also be stored at higher temperatures.That version should be ready by the end of the summer 2021. (01-01-2021)
Back to top
Britons are already being vaccinated
With the vaccine from Pfizer and BioNTech. But a crucial advantage of the AstraZeneca vaccine is that it can be kept in normal refrigerators. It can therefore be more easily used in nursing homes or at GP stations, for example. The UK medicines authority has approved the use of the corona vaccine from UK pharmaceutical company AstraZeneca and the University of Oxford. (30-12-2020)
RIVM: 'vaccination certificate' March 2021
Can only be downloaded at the end of March, not at the end of January. From the end of March 2021, it will be possible to view your own data about your vaccination against the corona virus, the RIVM reports. You can log in with DigiD via a website. The data can be downloaded to serve as proof of, for example. (04-01-2021)
Pharmaceutical Sanofi wrote on its own page
That scientists have to return to the drawing board due to "disappointing research results". The drug is said to induce a too small immune response in people over 50. The vaccine is said to be sufficiently effective in people between the ages of 18 and 49. (11-12-2020)
British and Russian pharmaceutical companies want to merge vaccines
British pharmaceutical company AstraZeneca and Russian authorities want to investigate whether their vaccines can be combined in development, researchers report Friday 11 December 2020. The Russian Sputnik V vaccine is said to have an effectiveness of more than 90 percent, while the AstraZeneca vaccine is effective in at least 70 percent of all cases. By combining both drugs, the pharmaceuticals hope for an even higher degree of effectiveness. Some tests were to be carried out before the end of the year 2020. The head of Russia's sovereign wealth fund, Kirill Dmitriev, suspects that the collaboration of scientists will become "crucial" to bring the pandemic to an end. (11-12-2020)
Russia vaccinating the population against the corona virus
Vaccination centers have been opened in Moscow, where teachers and people working in the healthcare sector can receive an injection. Russia claims it has an effectiveness of more than 90 percent, but the WHO health organization has yet to investigate that claim.
The vaccine Spoetnik V costs 16 euros per dose, but the Russian government vaccinates citizens for free. From the beginning of next year, people will need to be vaccinated across the country. In total, there would be two million doses in stock, Health Minister Mikhail Murashko said last week. (5-12-2020)
Back to top